GB2628229A - Methods and compositions for treating cancer - Google Patents
Methods and compositions for treating cancer Download PDFInfo
- Publication number
- GB2628229A GB2628229A GB2402730.2A GB202402730A GB2628229A GB 2628229 A GB2628229 A GB 2628229A GB 202402730 A GB202402730 A GB 202402730A GB 2628229 A GB2628229 A GB 2628229A
- Authority
- GB
- United Kingdom
- Prior art keywords
- administering
- group
- independently
- therapeutically
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract 54
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 201000000744 recessive dystrophic epidermolysis bullosa Diseases 0.000 claims abstract 9
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 3
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 230000003902 lesion Effects 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 238000002595 magnetic resonance imaging Methods 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical group FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- -1 hydroxy, sulfhydryl Chemical group 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000000565 sulfonamide group Chemical group 0.000 claims 2
- 125000001174 sulfone group Chemical group 0.000 claims 2
- 125000003375 sulfoxide group Chemical group 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010030178 Oesophageal obstruction Diseases 0.000 claims 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 1
- VLQLUZFVFXYXQE-USRGLUTNSA-M rigosertib sodium Chemical compound [Na+].COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC([O-])=O)=C1 VLQLUZFVFXYXQE-USRGLUTNSA-M 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232409P | 2021-08-12 | 2021-08-12 | |
| PCT/US2022/040092 WO2023018891A1 (en) | 2021-08-12 | 2022-08-11 | Methods and compositions for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202402730D0 GB202402730D0 (en) | 2024-04-10 |
| GB2628229A true GB2628229A (en) | 2024-09-18 |
Family
ID=85200519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2402730.2A Pending GB2628229A (en) | 2021-08-12 | 2022-08-11 | Methods and compositions for treating cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240299326A1 (https=) |
| EP (1) | EP4384498A1 (https=) |
| JP (1) | JP2024531238A (https=) |
| CN (1) | CN118076583A (https=) |
| AU (1) | AU2022326485A1 (https=) |
| CA (1) | CA3228644A1 (https=) |
| CO (1) | CO2024002786A2 (https=) |
| GB (1) | GB2628229A (https=) |
| IL (1) | IL310759A (https=) |
| MX (1) | MX2024001935A (https=) |
| WO (1) | WO2023018891A1 (https=) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090306207A1 (en) * | 2005-01-05 | 2009-12-10 | Reddy M V Ramana | Treatment of Drug-Resistant Proliferative Disorders |
| WO2017066552A1 (en) * | 2015-10-14 | 2017-04-20 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the treatment of epidermolysis bullosa |
| WO2019060719A1 (en) * | 2017-09-22 | 2019-03-28 | University Of Miami | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BULLETIN EPIDERMOLYSIS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089483A1 (en) * | 2012-12-07 | 2014-06-12 | Onconova Therapeutics, Inc. | Methods and compositions for treatment of cancer |
-
2022
- 2022-08-11 CA CA3228644A patent/CA3228644A1/en active Pending
- 2022-08-11 JP JP2024508686A patent/JP2024531238A/ja active Pending
- 2022-08-11 MX MX2024001935A patent/MX2024001935A/es unknown
- 2022-08-11 WO PCT/US2022/040092 patent/WO2023018891A1/en not_active Ceased
- 2022-08-11 AU AU2022326485A patent/AU2022326485A1/en active Pending
- 2022-08-11 IL IL310759A patent/IL310759A/en unknown
- 2022-08-11 GB GB2402730.2A patent/GB2628229A/en active Pending
- 2022-08-11 EP EP22856622.0A patent/EP4384498A1/en active Pending
- 2022-08-11 CN CN202280068270.9A patent/CN118076583A/zh active Pending
-
2024
- 2024-02-09 US US18/437,793 patent/US20240299326A1/en active Pending
- 2024-03-06 CO CONC2024/0002786A patent/CO2024002786A2/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090306207A1 (en) * | 2005-01-05 | 2009-12-10 | Reddy M V Ramana | Treatment of Drug-Resistant Proliferative Disorders |
| WO2017066552A1 (en) * | 2015-10-14 | 2017-04-20 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the treatment of epidermolysis bullosa |
| WO2019060719A1 (en) * | 2017-09-22 | 2019-03-28 | University Of Miami | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BULLETIN EPIDERMOLYSIS |
Non-Patent Citations (2)
| Title |
|---|
| Atanasova et al, "Identification of Rigosertib for the Treatment of Recessive...", pg. 3384-3391,Clinical Cancer Research * |
| Prasad et al, "ON 01910.Na (riosertib) inhibits P13K/Akt.pathway & activities..." pg 79388-79400, Oncotarget. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023018891A1 (en) | 2023-02-16 |
| US20240299326A1 (en) | 2024-09-12 |
| AU2022326485A1 (en) | 2024-02-29 |
| MX2024001935A (es) | 2024-03-21 |
| CO2024002786A2 (es) | 2024-03-18 |
| GB202402730D0 (en) | 2024-04-10 |
| CA3228644A1 (en) | 2023-02-16 |
| CN118076583A (zh) | 2024-05-24 |
| WO2023018891A8 (en) | 2023-09-21 |
| IL310759A (en) | 2024-04-01 |
| JP2024531238A (ja) | 2024-08-29 |
| EP4384498A1 (en) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103797001B (zh) | 苯并噻唑化合物及其药学上的应用 | |
| EP0778022B1 (en) | Use of rifamycin derivatives for the treatment of chlamydia infectous diseases | |
| CN109689042B (zh) | 用于治疗黄斑变性的与恩他卡朋相关的化合物 | |
| WO2009130242A1 (en) | Low molecular weight derivatives and use thereof in treatment of prostaglandin e synthase related diseases | |
| CA2395684A1 (en) | Sulfonamides and derivatives thereof that modulate the activity of endothelin | |
| CN101903045B (zh) | 用于治疗白内障的药物组合物 | |
| CA2446748A1 (en) | Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods | |
| JPS6016934A (ja) | 抗腫瘍剤 | |
| GB2628229A (en) | Methods and compositions for treating cancer | |
| JP2009523149A (ja) | ｍＴＯＲ阻害剤および抗葉酸化合物の組み合わせ | |
| CA2518195C (en) | Antitumor effect potentiator and antitumor agent | |
| JP3208437B2 (ja) | 癌転移抑制剤 | |
| HUP0203790A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére | |
| WO2023006993A1 (en) | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome | |
| CN112315964B (zh) | 环戊基菲啶苯类化合物在制备tln1蛋白抑制剂中的应用 | |
| JP4417424B2 (ja) | 発がん抑制剤 | |
| AU2008248188A1 (en) | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions | |
| US10080732B2 (en) | Compositions and methods for stimulating ventilatory and/or respiratory drive | |
| JPWO2023018891A5 (https=) | ||
| HK40114249A (zh) | 一种新型前列环素用於治疗肺高压 | |
| JP2876224B2 (ja) | 新規美白剤 | |
| HUP0203696A2 (hu) | Sejtburjánzásgátló hatású helyettesített bisz-indolil-maleimidek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| CN109293644B (zh) | 6-甲基烟酸甲酯在制备na抑制剂中的应用 | |
| CN118059102A (zh) | 一种延缓衰老的药物 | |
| CN119894861A (zh) | 一种新型前列环素用于治疗肺高压 |